Zealand Pharma A/S (CHIX:ZEALC) 3-Year EBITDA Growth Rate : 10.70% (As of Dec. 2023)

View and export this data going back to 2013. Start your Free Trial

What is Zealand Pharma A/S 3-Year EBITDA Growth Rate?

Zealand Pharma A/S's EBITDA per Share for the three months ended in Dec. 2023 was kr-4.53.

During the past 3 years, the average EBITDA Per Share Growth Rate was 10.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Zealand Pharma A/S was 13.10% per year. The lowest was -47.80% per year. And the median was -14.25% per year.

Competitive Comparison of Zealand Pharma A/S's 3-Year EBITDA Growth Rate

For the Biotechnology subindustry, Zealand Pharma A/S's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Zealand Pharma A/S's 3-Year EBITDA Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zealand Pharma A/S's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Zealand Pharma A/S's 3-Year EBITDA Growth Rate falls into.

Zealand Pharma A/S 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Zealand Pharma A/S (CHIX:ZEALc) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Zealand Pharma A/S 3-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Zealand Pharma A/S's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Zealand Pharma A/S (CHIX:ZEALC) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zealand Pharma A/S (CHIX:ZEALc) » Definitions » 3-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

ZLDPF:USA 0NZU:UK ZEAL:Denmark 22Z:Germany

Address

Sydmarken 11, Soborg, DNK, DK-2860

Website

https://www.zealandpharma.com

Zealand Pharma A/S is a biotechnology company. It is focused on the discovery, design, and development of peptide-based medicines. The company's product pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The company has out-licensed a peptide program to Boehringer Ingelheim that has been moved ahead into early clinical development: a once-weekly novel dual-acting GLP-1/glucagon agonist for the treatment of obesity and/or Type 2 diabetes.

Zealand Pharma A/S (CHIX:ZEALC) Headlines

No Headlines